Two River, LLC (“Two River”) and Vida Ventures (“Vida”), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics (“Candid”), a privately held ...
Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for immune resetCandid’s lead asset, cizutamig, a bispecific ...
Matthew C. Zorn previously argued that federal regulators determine "accepted medical use" through the FDA approval framework. Today, he appears on behalf of the United States defending a CMS program ...